Iijima Takahiro, Aoki Kazutaka, Kondo Yoshinobu, Terauchi Yasuo
Department of Endocrinology and Metabolism, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Department of Endocrinology, Diabetes and Metabolism, Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan.
J Clin Med Res. 2020 Feb;12(2):73-78. doi: 10.14740/jocmr4084. Epub 2020 Feb 1.
Recently, we reported that the level of lathosterol, a cholesterol synthesis marker, was suppressed after 1 month of treatment with anagliptin, a dipeptidyl peptidase-4 inhibitor. In this study, we administered either anagliptin or miglitol, an alpha-glucosidase inhibitor, for 3 months in patients with type 2 diabetes and compared the lipid-lowering effects of anagliptin with those of miglitol.
This study was a 12-week, open-label, prospective, randomized, parallel-group comparison trial. Fifty-two patients with type 2 diabetes who aged 20 - 70 years with a low-density lipoprotein cholesterol (LDL-C) level of over 120 mg/dL, and with no history of treatment with antihyperlipidemic drugs were enrolled. Patients were randomly assigned to either the anagliptin group or miglitol group. The 100 mg of anagliptin was administered twice a day for the anagliptin group and 50 mg of miglitol was administered thrice a day for miglitol group. The changes in lipids, cholesterol synthesis, and absorption markers were evaluated after 12 weeks.
Fifty-two participants were initially enrolled in the trial, and 47 of them completed the protocol. There was no significant difference in LDL-C, cholesterol synthesis, and the absorption markers between anagliptin and miglitol groups.
Anagliptin and miglitol are similarly effective on lipid and glycemic control.
最近，我们报道了胆固醇合成标志物羊毛甾醇的水平在使用二肽基肽酶-4抑制剂阿格列汀治疗1个月后受到抑制。在本研究中，我们对2型糖尿病患者给予阿格列汀或α-葡萄糖苷酶抑制剂米格列醇治疗3个月，并比较了阿格列汀与米格列醇的降脂效果。
本研究是一项为期12周的开放标签、前瞻性、随机、平行组比较试验。纳入了52例年龄在20 - 70岁、低密度脂蛋白胆固醇（LDL-C）水平超过120 mg/dL且无抗高脂血症药物治疗史的2型糖尿病患者。患者被随机分配到阿格列汀组或米格列醇组。阿格列汀组每天两次服用100 mg阿格列汀，米格列醇组每天三次服用50 mg米格列醇。12周后评估血脂、胆固醇合成和吸收标志物的变化。
最初有52名参与者纳入试验，其中47人完成了方案。阿格列汀组和米格列醇组在LDL-C、胆固醇合成和吸收标志物方面无显著差异。
阿格列汀和米格列醇在血脂和血糖控制方面效果相似。
